APA (7th ed.) Citation

Stintzing, S., Miller-Phillips, L., Modest, D., Fischer von Weikersthal, L., Decker, T., Kiani, A., . . . Heinemann, V. (2017). Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: Analysis of the FIRE-3 (AIO KRK-0306) study. European Journal of Cancer, 79, 50. https://doi.org/10.1016/j.ejca.2017.03.023

Chicago Style (17th ed.) Citation

Stintzing, S., et al. "Impact of BRAF and RAS Mutations on First-line Efficacy of FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab: Analysis of the FIRE-3 (AIO KRK-0306) Study." European Journal of Cancer 79 (2017): 50. https://doi.org/10.1016/j.ejca.2017.03.023.

MLA (9th ed.) Citation

Stintzing, S., et al. "Impact of BRAF and RAS Mutations on First-line Efficacy of FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab: Analysis of the FIRE-3 (AIO KRK-0306) Study." European Journal of Cancer, vol. 79, 2017, p. 50, https://doi.org/10.1016/j.ejca.2017.03.023.